共 50 条
- [21] ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancerINVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 599 - 607Crabb, Simon J.Birtle, Alison J.Martin, KarenDowns, NicholaRatcliffe, IanMaishman, TomEllis, MaryGriffiths, GarethThompson, StuartKsiazek, LidiaKhoo, VincentJones, Robert J.
- [22] Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Smyth, Lillian MaryReichel, Jonathan B.Tang, JiabinPatel, Juber Ahamad A.Meng, FanliSelcuklu, S. DuyguYou, DaoqiSamoila, AliaksandraSchiavon, GaiaLi, Bob T.Razavi, PedramPiscuoglio, SalvatoreReis-Filho, Jorge S.Nudis, Clifford A.Baselga, JoseSolit, David B.Taylor, Barry S.Hyman, David MichaelBerger, Michael F.Chandarlapaty, Sarat
- [23] The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial)CANCER RESEARCH, 2017, 77Roberston, J. F. R.Cheung, K. L.Ahmed, S.Coleman, R. E.Evans, A.Holcombe, C.Rea, D.Rauchhaus, P.Skene, A.Littleford, R.Jahan, A.Kelly, S.Lindermann, J. P. O.Horgan, K.Foxley, A.Rugman, P.Pass, M.
- [24] The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosisBRITISH JOURNAL OF CANCER, 2024, 131 (06) : 1080 - 1091Fang, MenghanLin, YoufenXue, ChaorongSheng, KaiqinGuo, ZegengHan, YutingLin, HanbinWu, YuechengSang, YuchaoChen, XintanHowell, Stephen B.Lin, XuLin, Xinjian
- [25] ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancerInvestigational New Drugs, 2017, 35 : 599 - 607Simon J. CrabbAlison J. BirtleKaren MartinNichola DownsIan RatcliffeTom MaishmanMary EllisGareth GriffithsStuart ThompsonLidia KsiazekVincent KhooRobert J. Jones
- [26] The AKT inhibitor AZD5363 is selectively active in PIK3CA mutant gastric cancer cell lines, and sensitizes a gastric cancer explant model to docetaxelCANCER RESEARCH, 2012, 72Li, JingDavies, Barry R.Zhou, MinhuaZhang, JingchuanXu, YanTang, LiliWang, HuiyingLiu, CharlesYin, XiaoluJi, QunshengYu, Derek Dehua
- [27] COMBINED TARGETING OF PI3K/AKT AND AR PATHWAY WITH AZD5363 AND ENZALUTAMIDE INDUCES ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCERJOURNAL OF UROLOGY, 2013, 189 (04): : E403 - E403Toren, PaulKim, SoojinGleave, MartinZoubeidi, Amina
- [28] A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell typeONCOLOGY LETTERS, 2016, 11 (03) : 1685 - 1692Zhang, YunchengZheng, YuanwenFaheem, AliSun, TiantongLi, ChunyouLi, ZheZhao, DiantangWu, ChaoLiu, Jun
- [29] AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3′-diindolylmethane in human breast cancer cellsTOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 429Zhu, KaiyuanLiu, XuLiu, ChunxiaoXu, YutingFu, YingqiangDong, WeiYan, YadongWang, WenjingQian, Cheng
- [30] Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT) (vol 26, pg 1574, 2020)CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5469 - 5469Robertson, John F. R.Coleman, Robert E.Cheung, Kwok-LeungEvans, AbigailHolcombe, ChrisSkene, AnthonyRea, DanielAhmed, SamreenJahan, AliHorgan, KieranRauchhaus, PetraLittleford, RobertaCheung, S. Y. AmyCullberg, Mariede Bruin, Elza C.Koulai, LoumpianaLindemann, Justin P. O.Pass, MartinRugman, PaulSchiavon, GaiaDeb, RahulFinlay, PaulineFoxley, AndrewGee, Julia M. W.